J
Jens Kristian Perregaard
Researcher at Lundbeck
Publications - 75
Citations - 2285
Jens Kristian Perregaard is an academic researcher from Lundbeck. The author has contributed to research in topics: Alkyl & Trifluoromethyl. The author has an hindex of 25, co-authored 75 publications receiving 2243 citations.
Papers
More filters
Journal ArticleDOI
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.
TL;DR: The pharmacological profile of the eutomers of citaloprams and N-demethylcitalopram very much resembles the profile ofThe respective racemates.
Journal ArticleDOI
Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats.
TL;DR: The results indicate that efficacies in the adenylate cyclase assay are dissociated from those on behaviour and indicate that in normal rats D-1 receptors are functionally relevant since D- 1 agonists facilitate the expression of oral stereotyped behaviour after combination with a D-2 agonist.
Journal ArticleDOI
.sigma. Ligands with Subnanomolar Affinity and Preference for the .sigma.2 Binding Site. 1. 3-(.omega.-Aminoalkyl)-1H-indoles
TL;DR: Potent anxiolytic activity in the black/white box exploration test in rats was found with the two most prominent sigma 2 ligands Lu 29-253 and Lu 28-179, and good penetration into the CNS was documented both after subcutaneous and peroral administration of Lu28-179 by ex vivo binding studies.
Journal ArticleDOI
Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
Connie Sanchez,Jørn Arnt,Nils Dragsted,John Hyttel,Hanne Løve Lembøl,Eddi Meier,Jens Kristian Perregaard,Torben Skarsfeldt +7 more
TL;DR: The pharmacological profile suggests that sertindole is an atypical neuroleptic compound with a low potential for extrapyramidal, autonomic, and anticholinergic side effects.
Patent
Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
TL;DR: The two enantiomers of the anti-depressant drug of the formula I ##STR1## are disclosed in this article, and methods for resolving intermediates and their steroselective conversion to a corresponding enatiomer of I are also disclosed.